In the placebo-controlled portion of pivotal trials, 2.2% of patients on placebo (n=902), 9.6% of patients on RINVOQ 15 mg (N=899), and 15.1% of patients on RINVOQ 30 mg (N=906) experienced adverse events of acne. 99% of cases were mild or moderate in severity. Two events led to study discontinuation (1 each in the 15 mg and 30 mg groups).